Canadian Sec - Delayed Quote CAD
Biosenta Inc. (ZRO.CN)
At close: November 15 at 3:00 PM EST
Breakdown
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Total Revenue
200.9800
1.0420
1.1510
168.1050
1.5300
Cost of Revenue
0.5310
0.6150
0.4230
68.9980
1.4750
Gross Profit
200.4490
0.4270
0.7280
99.1070
0.0550
Operating Expense
1,298.4900
1,446.9010
1,197.5120
2,118.7410
728.6480
Operating Income
-1,098.0410
-1,446.4740
-1,196.7840
-2,019.6340
-728.5930
Net Non Operating Interest Income Expense
-851.5270
-64.3650
-222.8780
-10.2490
-37.6530
Other Income Expense
-4,790.6170
-4,788.9150
-38.5990
-11.9860
4.3380
Pretax Income
-6,740.1850
-6,299.7540
-1,458.2610
-2,041.8690
-761.9080
Net Income Common Stockholders
-6,740.1850
-6,299.7540
-1,458.2610
-2,041.8690
-761.9080
Diluted NI Available to Com Stockholders
-6,740.1850
-6,299.7540
-1,458.2610
-2,041.8690
-761.9080
Basic EPS
-0.24
-0.24
-0.07
-0.11
-0.05
Diluted EPS
-0.24
-0.24
-0.07
-0.11
-0.05
Basic Average Shares
30,438.6920
26,147.1130
21,303.4900
17,796.5460
15,994.1730
Diluted Average Shares
30,438.6920
26,147.1130
21,303.4900
17,796.5460
15,994.1730
Total Operating Income as Reported
-1,106.4590
-1,509.9620
-1,208.2960
-2,019.6340
-728.5930
Total Expenses
1,299.0210
1,447.5160
1,197.9350
2,187.7390
730.1230
Net Income from Continuing & Discontinued Operation
-6,740.1850
-6,299.7540
-1,458.2610
-2,041.8690
-761.9080
Normalized Income
-1,949.5680
-1,510.8390
-1,419.6620
-2,029.8830
-766.2460
Interest Expense
851.5270
64.3650
222.8780
10.2490
37.6530
Net Interest Income
-851.5270
-64.3650
-222.8780
-10.2490
-37.6530
EBIT
-5,888.6580
-6,235.3890
-1,235.3830
-2,031.6200
-724.2550
EBITDA
-5,888.6580
-6,235.3890
-1,235.3830
-2,031.6200
-724.2550
Reconciled Cost of Revenue
0.5310
0.6150
0.4230
68.9980
1.4750
Net Income from Continuing Operation Net Minority Interest
-6,740.1850
-6,299.7540
-1,458.2610
-2,041.8690
-761.9080
Total Unusual Items Excluding Goodwill
-4,790.6170
-4,788.9150
-38.5990
-11.9860
4.3380
Total Unusual Items
-4,790.6170
-4,788.9150
-38.5990
-11.9860
4.3380
Normalized EBITDA
-1,098.0410
-1,446.4740
-1,196.7840
-2,019.6340
-728.5930
9/30/2020 - 5/5/2010
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade